Study Shows New Drug Helps Diabetes Patients
From Associated Press
Amylin Pharmaceuticals Inc., Eli Lilly & Co. and Alkermes Inc. said results from a mid-stage study showed that a long-acting form of their Byetta injection helped patients with Type 2 diabetes improve glucose control.
The companies said that after 15 weeks, the once-weekly doses of exenatide LAR were well tolerated and the expected therapeutic blood levels were achieved. Dose-dependent improvements in hemoglobin A1C -- a measure of glucose control -- and weight loss also were observed.
Shares of Alkermes were up $1.17, or 7.4%, at a 52-week high of $17 in after-market activity. Shares of Amylin soared 25%, or $5.57, to a year-high $27.50 after hours. Eli Lilly shares rose 14 cents to $52.71 in regular trading.
